Company facts
- Industry
- Services-Medical Laboratories
- Headquarters
- Secaucus, New Jersey
- Most recent report
- 10-Q, filed Oct 23, 2026
- Incorporated
- Delaware
- Filings on record
- 1,001+ filings
- On EDGAR
- CIK 1022079
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 41
News 8 of 122
Prospectuses and Registrations 8 of 25
- 424B2 Prospectus supplement for an offering Apr 28, 2026
- FWP Free writing prospectus Apr 27, 2026
- 424B2 Prospectus supplement for an offering Apr 27, 2026
- S-3ASR Automatic shelf registration Jun 20, 2025
- 424B2 Prospectus supplement for an offering Aug 16, 2024
- FWP Free writing prospectus Aug 15, 2024
- 424B2 Prospectus supplement for an offering Aug 15, 2024
- 424B2 Prospectus supplement for an offering Oct 31, 2023
Proxies 8 of 28
- DEFA14A Extra proxy material Apr 6, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 6, 2026
- DEFA14A Extra proxy material Apr 11, 2025
- DEFA14A Extra proxy material Apr 4, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 4, 2025
- PX14A6G Shareholder's own proxy material Apr 11, 2024
- DEFA14A Extra proxy material Apr 5, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 5, 2024
Ownership 8 of 773
- 144 Notice of a proposed sale of restricted stock Nov 9, 2026
- 4 Insider reported a trade Nov 5, 2026
- 4 Insider reported a trade Nov 5, 2026
- 4 Insider reported a trade Nov 5, 2026
- 3 Insider reported their initial holding Nov 5, 2026
- 144 Notice of a proposed sale of restricted stock Nov 3, 2026
- 4 Insider reported a trade Oct 28, 2026
- 144 Notice of a proposed sale of restricted stock Oct 26, 2026
Other 8 of 12
- 11-K Employee stock plan report Jun 18, 2026
- 11-K Employee stock plan report Jun 20, 2025
- 11-K Employee stock plan report Jun 21, 2024
- 11-K Employee stock plan report Jun 22, 2023
- 11-K Employee stock plan report Jun 23, 2022
- 11-K Employee stock plan report Jun 28, 2021
- 11-K Employee stock plan report Jun 29, 2020
- 11-K Employee stock plan report Jun 27, 2019
What to read: Sep 2026 10-Q
SECSift found 4 of 10 sections worth reading, with 2 positive, 12 notable, and 0 negative flags.
Part I
Core financial statements with material changes in debt, equity, and cash flows.Notable- Corewell Health JV added $179M goodwill and $124M intangible assets; 51% owned, consolidated.
- Issued $500M of 5.00% senior notes due 2036, using proceeds to repay $500M of 3.45% notes due June 2026.
- Dividend raised to $0.86/quarter in 2026 from $0.80 in 2025, a 7.5% increase.
- Repurchased $250M of stock in nine months 2026, up from $150M a year ago; $1.2B remains authorized.
- Legal reserves increased to $32M from $20M; general/professional liability reserves steady at $180M.
Management's Discussion (Item 2)
Full MD&A with detailed operating results, segment metrics, and liquidity analysis.PositiveNotable- Corewell Health venture closed Jan 2026; Quest consolidates entity with 51% ownership.
- Invigorate program aims for 3% annual cost savings; $14M in restructuring charges in nine months.
- Volume up 14.5% in Q3 2026; 9.5% from Corewell Health and Fresenius Medical Care contracts.
- Revenue per requisition fell 4.2% in Q3 2026 due to mix from new low-acuity contracts.
- Days sales outstanding rose to 51 days as of Sep 30, 2026 from 48 at Dec 31, 2025.
Unregistered Sales and Repurchases (Item 2)
Company resumed buybacks in Sept 2026 after two months of pause; $1.18B remaining.Other Information (Item 5)
Five senior insiders adopted new 10b5-1 sell plans, including the CEO for up to 172,095 shares.
What changed: Sep 2026 vs. Jun 2026
About 2% of DGX's Sep 2026 10-Q is new information. 7 paragraphs were added, 160 changed, and 8 removed. Below are the most important lines SECSift identified.
Changed
- Invigorate program charges for nine months ended Sep 30, 2026: $14M pre-tax, $10M employee separation costs.
- Cash and cash equivalents rose to $797 million from $420 million at December 31, 2025.
- Noncontrolling interests rose to $318 million from $36 million at December 31, 2025.
- Reserves for general and professional liability claims rose to $180 million from $178 million at December 31, 2025.
- XBRL calculation file changed from dgx-20260630_cal.xml to dgx-20260930_cal.xml.
- XBRL definition file changed from dgx-20260630_def.xml to dgx-20260930_def.xml.
- XBRL label file changed from dgx-20260630_lab.xml to dgx-20260930_lab.xml.
- XBRL schema file changed from dgx-20260630.xsd to dgx-20260930.xsd.
Everything here comes from Quest Diagnostics Inc's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Oct 24, 2026, from the 10-Q for Sep 2026.